Since Trump took office on January 20, research funding from the National Institutes of Health has plummeted by more than $3 billion compared with the pace of funding in 2024, according to an analysis by The Washington Post.

By this time in March 2024, the NIH had awarded US researchers a total of $1.027 billion for new grants or competitive grant renewals. This year, the figure currently stands at about $400 million. Likewise, funding for renewals of existing grants without competition reached $4.5 billion by this time last year, but has only hit $2 billion this year. Together, this slowdown amounts to a 60 percent drop in grant support for a wide variety of research—from studies on cancer treatments, diabetes, Alzheimer’s, vaccines, mental health, transgender health, and more.

The NIH is the primary source of funding for biomedical research in the US. NIH grants support more than 300,000 scientists at more than 2,500 universities, medical schools, and other research organizations across all 50 states.

In the near term, the missing grant money means clinical trials have been abruptly halted, scientific projects are being shelved, supplies can’t be purchased, and experiments can’t be run. But, in the long run, it means a delay in scientific advancements and treatment, which could echo across future generations. With funding in question, academic researchers may be unable to retain staff or train younger scientists.